Ogeda SA→Astellas Pharma
Acquisition · Cash + milestone payments · announced Apr 3, 2017
Announced
Apr 3, 2017
Closed
May 17, 2017
Economics
Cash + milestone payments()
Pre-deal · pre-deal mark: 2017, year precision · rounding grid ±$100M · Astellas press release — Ogeda SA acquisition, 2017
EUR 500M upfront + up to EUR 300M development milestones; ~$560M USD at 2017 exchange rates
Target
Ogeda SA
Menopause · Clinical / therapeutic
HQ Gosselies, Belgium · Founded 1999
Drug discovery company developing fezolinetant for menopausal vasomotor symptoms; formerly Euroscreen SA
- Astellas Pharma press release (May 17, 2017)
- PR Newswire - Astellas completes acquisition (May 2017)
- Astellas newsroom - newsroom.astellas.com
Acquirer
Astellas Pharma
Healthcare
HQ Tokyo, Japan
Japanese pharmaceutical company focused on urology, oncology, and women's health
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Added fezolinetant (NK3 receptor antagonist) for menopausal vasomotor symptoms — later FDA-approved as VEOZAH in 2023
Evidence ladder
Secondary (press / IR)
Astellas Pharma press release (May 17, 2017)
Secondary (press / IR)
PR Newswire
Limitations
- Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
- EUR 500M upfront + up to EUR 300M development milestones; ~$560M USD at 2017 exchange rates
- Pre-deal valuation sourced from: Astellas press release — Ogeda SA acquisition, 2017. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Menopause
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| KaNDy Therapeutics | Bayer | Aug 11, 2020 | same evidence class |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Ogeda SA (Menopause). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.